Skip to main content
BMJ Open logoLink to BMJ Open
. 2017 Sep 27;7(9):e016408. doi: 10.1136/bmjopen-2017-016408

Interactions between physicians and the pharmaceutical industry generally and sales representatives specifically and their association with physicians’ attitudes and prescribing habits: a systematic review

Freek Fickweiler 1, Ward Fickweiler 1, Ewout Urbach 1
PMCID: PMC5623540  PMID: 28963287

Abstract

Objectives

The objective of this review is to explore interactions between physicians and the pharmaceutical industry including sales representatives and their impact on physicians’ attitude and prescribing habits.

Data sources

PubMed, Embase, Cochrane Library and Google scholar electronic databases were searched from 1992 to August 2016 using free-text words and medical subject headings relevant to the topic.

Study selection

Studies included cross-sectional studies, cohort studies, randomised trials and survey designs. Studies with narrative reviews, case reports, opinion polls and letters to the editor were excluded from data synthesis.

Data extraction

Two reviewers independently extracted the data. Data on study design, study year, country, participant characteristics, setting and number of participants were collected.

Data synthesis

Pharmaceutical industry and pharmaceutical sales representative (PSR) interactions influence physicians’ attitudes and their prescribing behaviour and increase the number of formulary addition requests for the company’s drug.

Conclusion

Physician–pharmaceutical industry and its sales representative’s interactions and acceptance of gifts from the company’s PSRs have been found to affect physicians’ prescribing behaviour and are likely to contribute to irrational prescribing of the company’s drug. Therefore, intervention in the form of policy implementation and education about the implications of these interactions is needed.

Keywords: pharmaceutical sales representative; physicians, drug industry; brand prescriptions; conflict of interest; physicians-industry interactions; pharmaceutical industry; attitude of health personnel; gifts to physicians; medical education; irrational prescriptions


Strengths and limitations of this study.

  • Large up-to-date systematic review of studies exploring the impact of pharmaceutical industry representative interactions on physicians.

  • This systematic review used the recommendations outlined in the Cochrane Handbook for conducting systematic reviews and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology to assess the quality of the evidence by outcome.

  • PubMed, Embase, Cochrane Library and Google Scholar electronic databases were searched from 1992, as well as grey literature.

  • Most studies identified were observational and of varying methodological design.

  • Some studies did not provide evidence for the significance of their findings.

Introduction

The relationship between physicians and the pharmaceutical industry has evoked heated debate for many decades.1 In 2012, the pharmaceutical industry spent $89.5 billion on physician–pharmaceutical sales representative (PSR) interactions that accounted for 60% of the global sales and marketing spending.2–8 Previous reports have demonstrated that PSRs may influence prescribing behaviour.9–16 However, the evidence determining whether pharmaceutical industry and PSRs interactions influence physicians is divided and contradictory. Studies have indicated that physicians may be unable to distinguish between promotional information and scientific evidence.17 18 Physicians, however, believe their colleagues are more susceptible to pharmaceutical industry marketing strategies than themselves.19–22 The majority of the physicians do not believe that they are affected by pharmaceutical industry and PSR interactions. Most medical and governmental institutions have installed guidelines and self-regulatory and legislative checks to regulate the relationship between physicians and the pharmaceutical industry and its representatives.5 15 16 23–26 However, while administrative proposals for deregulatory reforms that would remove some governmental authority over the industry are increasing, scientific evidence rigorously examining the extent of interactions between physicians and pharmaceutical industry and it PSRs is needed. This review evaluates critically and systemically the evidence on the impact of pharmaceutical industry and PSR interactions on physicians.

Methodology

Protocol

We followed a detailed methodology that we described in our review protocol, which is available on request to the corresponding author. Two independent reviewers assessed selected articles as per inclusion/exclusion criteria, shortlisted them for writing the review and cross-checked their decisions about inclusion/exclusion with each other. The review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (supplementary appendix 1).

Supplementary Appendix 1

bmjopen-2017-016408supp001.pdf (317.1KB, pdf)

Eligibility criteria

The eligibility criteria were:

  • types of studies: observational study design, such as cross-sectional studies and cohort studies, but also (non-)randomised trials and survey designs comparing at least one facet that are mentioned below on the impact on behaviour and attitude;

  • types of participants: physicians, pharmaceutical representatives and physicians in training/residents;

  • types of exposure: any type of interaction between physicians and the pharmaceutical industry where there is direct interaction with the physician, such as meeting with drug representatives, participating in pharmaceutical-sponsored Continuing Medical Education (CME) events, receiving travel funding, free drug samples, industry-provided meals, gifts and presentations of industry-related information;

  • types of outcome: knowledge, beliefs and/or attitudes of physicians regarding physician–industry interactions and (prescribing) behaviour of physicians;

  • type of control: no interaction.

  • Exclusion criteria were: qualitative, ecological, econometric studies, editorials, letters to the editor, studies on other health professionals (eg, nurses and medical students), small samples sizes, studies assessing indirect interactions and research funding.

We did not exclude studies based on risk of bias. We took risk of bias into account when grading the quality of evidence using GRADE approach.

Search strategy

The search strategy included PubMed, Embase, Cochrane Library and Google Scholar electronic databases (January 1992 to August 2016). Databases were not searched before 1992, as these studies were already investigated in an earlier review.27 The search combined terms for physicians and pharmaceutical and included both free-text words and medical subject heading relevant to the topic. We did not use a search filter. The online supplementary information file provides the full details for one database. Additional search strategies included a search of the grey literature (theses and dissertations). Also, we reviewed the references lists of included and relevant papers.27–29

Supplementary material 2

bmjopen-2017-016408supp002.pdf (179.5KB, pdf)

Assessment of risk of bias in included studies

Two reviewers assessed in duplicate and independently the risk of bias in each eligible study. Disagreements were resolved by discussion or adjudication by a third reviewer. We used the recommendations outlined in the Cochrane Handbook to assess the risk of bias in randomised studies. We graded each potential source of bias and rated the studies as high, low or unclear risk of bias.

Data analysis and synthesis

The information extracted from the selected studies included type of study, study design, type of pharmaceutical industry and PSR interaction and type of outcome. We did not conduct a meta-analysis due to the heterogeneity of study design, types of interventions, outcomes assessed and outcome measures used. Instead, we summarised the data narratively. We assessed the quality of evidence by outcome using the GRADE methodology.30

Results

We independently screened the titles and abstracts of the 2170 identified records for potential eligibility. Out of 2170, the full text of 49 eligible citations that matched the inclusion criteria were retrieved and used for qualitative assessment during the writing of the review (figure 1, table 1).

Figure 1.

Figure 1

PRISMA flow diagram showing search strategy and included studies. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.

Table 1.

Characteristics of included studies

Study Authors Country Time frame Participants, setting Study design Interaction Outcomes
1 Steinman et al 1 USA Spring 1999 Surveys about attitudes and behaviours towards industry gifts in 105 residents at a university-based internal medicine residency programme Cross-sectional PSR interactions, gifts Most participants (61%) hold positive attitudes towards gifts from industry and PSR interactions and believe they do not influence their own prescribing, but only 16% believed other physicians were similarly unaffected (p<0.0001)
11 De Ferrari et al 9 Peru March 2013 Questionnaire in 155 faculty and trainee physicians of five different clinical departments working in a public general hospital Cross-sectional PSR interactions, medical samples, promotional material, dinners Positive attitude towards representatives (88.5% of participants). Faculty physicians received a larger amount of medical samples and promotional material and were more prone to believe that gifts and lunches do not influence their prescribing behaviour (42.2% vs 23.6%; p=0.036)
12 Thomson et al 31 New Zealand 1991 Questionnaire survey of 67 general practitioners Cross-sectional Interactions with PSR Most general practitioners (67%) had a negative attitude towards PSR interaction
13 Kamal et al 32 Egypt July and August 2013 Interviews with 18 physicians Cross-sectional Interaction with PSR Positive attitude towards PSR interaction
14 Hodges10 Canada October 1993–February 1994 Survey in 105 residents of psychiatry Cross-sectional Interaction with PSR, drug samples, lunches Positive attitude towards PSR interaction (56.5% of participants). The more money and promotional items a participant had received, the more likely he or she was to believe that discussions with representatives did not affect prescribing (p<0.05)
15 Gibbons et al 33 USA Not reported Survey of 392 physicians in two tertiary care medical centres Cross-sectional PSR interactions, gifts, samples, travel, lunches Positive attitude towards PSR interactions, gifts, samples and lunches
16 Spingarn et al 56 USA February 1990 75 internal medicine physicians in university medical centre Retrospective cohort PSR interaction (teaching) Attendees inappropriately prescribed PSR speakers drug compared with non-attendees (p=0.029)
17 Zaki58 Saudi Arabia September–November 2013 Survey of 250 physicians Randomised, cross-sectional survey Conferences, drug samples Favourable towards promotion
18 Orlowski et al 199457 USA 1987–1989 10 physicians that were invited for a symposium and tracking the pharmacy inventory usage reports for these drugs before and after the symposia Cohort Conference travel Significant increase in the prescribing pattern of drugs occurred following the symposia (p<0.001)
19 Scheffer et al 34 Brazil 2007–2009 Survey of 300 physicians prescribing antiretroviral drugs Cross-sectional Interaction with representative, drug samples, journals Frequency of interaction; the majority of (64%) of the physicians had multiple forms of interactions with PSR
20 Brett et al 35 USA Not reported Questionnaire of 93 physicians in a medical school Cross-sectional Interaction with PSR Impact on attitudes; most physicians believed that most of PSR activities do not pose major ethical problems
21 Gupta et al 36 India June–September 2014 Survey of 81 physicians in single hospital Cross-sectional Interaction with representative, drug samples, journals Impact on prescribing; 61.7% of participants think that PSR has an impact on their prescribing (p=0.0001)
22 Morgan et al 37 USA March 2003 Survey of 397 obstetrician-gynaecologists Cross-sectional Drug samples, promotional material, lunch Impact on prescribing, positive attitudes; most respondents thought it is proper to accept drug samples (92%), lunch (77%), an anatomical model (75%) or a well-paid consultantship (53%) from PSR
23 Alosaimi et al 19 Saudi Arabia 2012 Survey of 659 physicians Cross-sectional Interaction with PSR Positive attitude towards PSR interaction
24 Chren and Landefeld61 USA 1989–1990 40 case physicians and 80 control physicians Case–control PSR interactions, honoraria, research Increased prescription of company’s drug after PSR interaction, honoraria and research (p<0.001, all)
25 Randall et al 59 USA October 2001 Intervention group of physicians (n=18) that received education about PSR interaction and control group (n=14) Controlled trial Interaction with PSR The majority of residents found the interactions and gifts useful. Compared with the comparison group, the intervention group significantly decreased the reported number of office supplies and non-educational gifts (p<0.05)
26 Caudill et al 38 USA Not reported Survey of 446 primary care physicians Cross-sectional Interaction with PSR Significant positive correlation between physician cost of prescribing and perceived credibility, availability, applicability and use of information provided by PSR (p<0.01)
27 Andaleeb and Tallman20 USA Not reported 223 physicians in northwestern Pennsylvania Cross-sectional Interaction with PSR Positive attitude towards PSR interaction
28 Reeder et al 39 USA 1991–1992 87 residents of emergency medicine Cross-sectional Interaction with PSR, gifts Most participants believed that PSR interaction had no impact on their prescribing
29 Lichstein et al 40 USA January–March 1990 272 directors of internal medicine residency programmes Cross-sectional Interaction with PSR Most participants had a positive attitude towards PSR interactions
30 Brotzman et al 41 USA Not reported Directors of 386 family practice residency programme Cross-sectional Interaction with PSR Majority of programmes do not have guidelines for interaction with PSR
31 Alssageer and Kowalski42 Libya August–October 2010 Survey of 608 physicians in public and private practice settings Cross-sectional Interaction with PSR, drug samples, printed materials Positive attitude towards PSR interactions
32 Lieb and Brandtonies, 201021 Germany 2007 Survey of 208 physicians (neurology, cardiology and general medicine) Cross-sectional Interaction with PSR, drug samples, printed materials, lunches Frequency and impact on attitudes
33 Lieb and Scheurich22 Germany 2010–2011 Survey of 160 physicians in private and public practices Cross-sectional Interaction with representative, drug samples, printed materials, CME High expenditure prescribing; avoidance of industry-sponsored CME is associated with more rational prescribing habits
34 Lieb and Koch,43 Germany May–July 2012 Survey of 1038 medical students at eight universities Cross-sectional Interaction with representative, drug samples, printed materials, lunches Most participants have contact with the pharmaceutical company; 24.6% of the participants thought gifts would influence their future prescribing behaviour, while 45.1% thought gifts would influence their classmates’ future prescribing behaviour (p<0.001)
35 Brown et al 44 USA 2008 and 2013 251 directors of family medicine residency programmes Cross-sectional Interaction with PSR, gifts, lunches Negative attitude towards PSR interactions
37 Rahman et al 45 Bangladesh December 2008–January 2009 Survey of 83 village physicians Cross-sectional Interaction with PSR Impact on their prescribing
38 Lee and Begley,12 USA 2008 Nationally representative survey of 4720 physicians Cross-sectional Gifts Gifts were associated with lower perceived quality of patient care; an inverse relationship between the frequency of received gifts and the perceived quality of care was observed
39 Montastruc et al 13 France August–October 2011 Survey among 631 medical residents Cross-sectional Interaction with representative Most participants believed that PSR interaction had no impact on their prescribing; participants who had a more positive opinion were more frequently exposed to PSR (p<0.001)
40 Klemenc-Ketis and Kersnik46 Slovenia October 2011 895 family physicians at the primary level of care Cross-sectional Interaction with PSR Positive effect on knowledge; participants value PSRs’ selling and communication skills and trustworthiness highly
41 Hurley et al 47 USA 2010 3500 dermatologists Cross-sectional Free drug samples Impact on their prescribing; the provision of samples with a prescription by dermatologists has been increasing over time, and this increase is correlated (r=0.92) with the use of the branded generic drugs promoted by these sample
42 Makowska48 Poland November–December 2008 Survey of 382 physicians Cross-sectional Gifts Positive attitude towards PSR interactions
43 Siddiqui et al 49 Pakistan Not reported Questionnaires of 352 medical students Cross-sectional Interaction with representative Positive attitude towards PSR interaction
55 Workneh et al 50 Ethiopia February–March 2015 Survey of 90 physicians from public and private health facilities Cross-sectional Interaction with representative, gifts Positive attitude towards industry, impact on prescribing behaviour; nearly half of the physicians reported that their prescribing decisions were influenced by PSR
57 Khan et al 51 Pakistan Not reported Questionnaires in 472 physicians Cross-sectional Interaction with representative, gifts Positive attitude towards PSR interaction
58 Saito et al 67 Japan January–March 2008 1417 physicians working in internal medicine, general surgery, orthopaedic surgery, paediatrics, obstetrics-gynaecology, psychiatry and ophthalmology National survey Interaction with industry, receipt of gifts, funds, CME, samples Positive attitude towards PSR and gifts, value information from PSR, interactions higher with physicians who prefer to prescribe brand names
59 Ziegler18 USA 1993 27 physicians working in public and private hospitals Survey Accuracy of information provided by PSRs about drugs Incorrect information often provided by speakers goes unnoticed by physicians
60 Lurie et al 68 USA Not reported 240 internal medicine faculty physicians in academic medical centres Survey Effect of interaction with PSR, free meals, honoraria and research support Impact on prescribing behaviour and formulary change requests
62 DeJong et al 52 USA August–September 2013 279 669 physicians who wrote Medicare prescriptions in any of four drug classes: statins, cardioselective β-blockers, ACE inhibitors and angiotensin-receptor blockers, and selective serotonin and serotonin-norepinephrine reuptake inhibitors Physicians Cross-sectional Industry-sponsored meals Receipt of industry-sponsored meals was associated with an increased rate of brand name prescription.
63 Yeh et al 53 USA 2011 All licensed Massachusetts physicians who wrote prescriptions for statins paid for under the Medicare drug benefit in 2011 (n=2444) Cross-sectional Effect of industry payment on prescription of branded drugs for cholesterol control Payment for meals and educational programmes increased prescription of brand name statins.
65 Bowman and Pearle et al 69 USA Not reported 121 physician attendees Self-report survey Effect of CME on prescribing behaviour Sponsoring company’s drugs were favoured during prescription
66 Fischer et al 65 USA November 2006–March 2007 Multidisciplinary focus groups with 61 physicians Survey Effect of industry marketing strategies on prescription and cognitive dissonance of physicians Most participants reported no PSR impact on their prescribing, value to have ability to evaluate information of PSRs
67 Chimonas et al 66 USA June 2004 Six focus groups in 32 academic and community physicians Survey PSR interactions Positive attitude towards PSR interaction
72 Yeh et al 54 USA Not reported 1610 US medical students Cross-sectional Interaction with representative, gifts, lunches Policies separating students from representatives reduced number of interactions
73 Larkin et al 73 USA January 2006–June 2009 Paediatricians, child and adolescent psychiatrists in five medical centres Survey Interaction with PSR Antidetailing policies reduced the prescription of off-label antidepressants and antipsychotics for children
74 Esmaily et al 60 Iran Not reported 112 general physicians were randomised in two groups: (1) outcome-based educational intervention for rational prescribing and (2) concurrent CME programme in the field of rational prescribing Randomised trial Effect of outcome and retinal prescribing Rational prescribing improved in some of the important outcome-based indicators. No difference between two arms of the study
76 Parikh et al 55 USA 2014 Descriptive, cross-sectional analysis of Open Payments data and 9 638 825 payments to physicians and paediatricians from 1 January to 31 December 2014 Cross-sectional Comparison of PSR interactions between paediatricians and other specialists; among subspecialties of paediatrics. Paediatricians get fewer gifts from PSR than internists. There is variation among subspecialties for extent of interaction.
78 Chressanthis et al 74 USA Not reported Clinical decisions of 72 114 physicians were statistically analysed using prescription data Survey Effect of restricting PSRs on clinical practice and knowledge Restricting PSRs affected information flow about drugs, both negative and positive.

We excluded 2000 records as they were not relevant (n=1641), not original research (n=269), about medical students (n=4) and non-medical (eg, ecological and econometric; n=86).

PSRs, pharmaceutical sales representatives.

Characteristics of included studies

The identified studies were published between 1992 and August 2016. Most of the studies included were cross-sectional studies.1 9–13 19 21 22 31–55 Only two studies were cohort studies,56 57 three were randomised trials58–60 and one study was a case–control study.61

Extent of interactions between physicians and the pharmaceutical industry

We found that PSR interactions are a regular feature in the daily lives of physicians across the world.9–11 13 42 50 Most of the attending physicians and residents have at least one interaction with industry representatives per month.10 21 22 36 42 The frequency of interactions or gifts offered and accepted varies with private versus public hospital setting and the position of the physicians in the medical hierarchy.10 13 31 38 42 43 50 58 62 Junior residents received twice as much free drug samples from PSR interactions than senior residents.10 PSR interactions were significantly higher at the beginning of residency.13 The majority of programme directors of internal medicine residencies in the USA allowed PSRs to meet with residents during working hours and permitted PSR sponsorship of conferences.40 Attending physicians and physician specialists had more PSR interactions and received higher numbers of medical samples and promotional material than residents.9 42 Participants working in private practice alone or in both sectors were more likely to receive gifts than physicians working in the public sector.38 42 50 Most common gifts received were medical samples,9 21 22 31 36 37 42 63 promotional material9 34 42 invitations for dinners,9 invitations for CMEs,22 34 scientific journals34 and free lunches.21 37

Perspectives of physicians towards PSR interactions

We found that physicians have a positive attitude towards PSRs1 13 19 20 22 31 32 40 49 58 64 Physicians perceived PSRs as important sources of education and funding,10 22 32 43 45 46; while some studies reporting sceptical attitudes about the contribution of PSRs towards teaching and education.21 36 39 40 49 Conference registration fees, informational luncheons, sponsorship of departmental journal clubs, anatomical models and free drug samples were considered as appropriate gifts.19 39 51 58 Most of the physicians considered pharmaceutical information provided by PSRs, industry-sponsored conferences and CME events as important instruments for enhancing their scientific knowledge.22 32 45 46 Compared with senior residents, significantly more junior residents felt that pharmaceutical representatives have a valuable teaching role.10

Most studies found that physicians do not believe that PSR interactions impact their prescribing behavoir,1 9–13 65 66 while other studies found that there was some extent of influence.21 22 34 36 37 39 43 In addition, physicians considered their colleagues more susceptible than themselves to PSR marketing strategies.1 20 21 37 43 There was a strong correlation between the amount of gifts and the belief that PSR interactions did not influence their prescribing behaviour.10

Gifts

We found that better scores on knowledge and attitudes were significantly associated with fewer interactions with representatives and their gifts.19 Conference registration fees, informational luncheons, sponsorship of departmental journal clubs, anatomical models and free drug samples were considered as appropriate gifts19 37 47 52 Most of the physicians considered themselves immune to the influence of gifts.1 10 32 33 35 39 53 58 Most common gifts received were medical samples,9 21 22 31 36 37 42–44 47 promotional material,9 34 42 67 invitations for dinners9 and scientific journals.34

Drug samples

Most of the physicians who accepted drug samples had a positive attitude towards the pharmaceutical representatives.9 21 22 31 36 37 42 43 Accepting samples lead to higher branded drug prescription rather than generic prescribing.22 47

Pharmaceutical representative speakers

Sponsored lectures/symposia of pharmaceutical companies influenced behaviour of the attendees leading to the attendees prescribing more drugs from the sponsoring companies without sufficient evidence supporting superiority of those drugs.56 57 The majority of attending physicians failed to identify inaccurate information about the company drug.18

Honoraria and research funding

Physicians who received money to attend pharmaceutical symposia or to perform research requested formulary addition of the company’s drug more often than other physicians. This association was independent of many confounding factors61 (table 2). Brief encounters with PSRs and receipt of honoraria or research support were predictors of faculty requested change in hospital formulary.68

Table 2.

Impact of physician–pharmaceutical industry interaction on physician

# Attitudes Prescribing behaviour Knowledge Formulary requests Quality of evidence (GRADE)
Gifts Receiving higher number of gifts associated with belief that PSR (pharmaceutical representative) have no impact on their prescribing behaviour1 14 39 Moderate
Drug samples Positive attitude towards the drug industry and the representatives11 21 34 Higher prescription of the company drug21 41 High
Pharmaceutical representative speakers Irrational prescribing
16 18 34
Inability to identify false claims16 Increased prescription of sponsor’s drug24 High
Honoraria and research funding Positive attitude towards sponsor’s drug60 Increased prescription of sponsor’s drug24 Low
Conference travel Significant increase in prescribing of sponsor drug18 Increased prescription of sponsor’s drug24 Low
Industry-paid lunches Positive attitude towards sponsor’s drug14 34 Significant increase in prescribing of sponsor drug62 Increased formulary request for company drug11 21 High
CME sponsorship Positive attitude towards sponsor’s drug24 65 Avoidance of industry-sponsored CME associated with more rational prescribing habits33 Moderate
Interaction withPSR Positive attitude towards PSR drugs1 11 14 58 Higher prescription of the company drug24 Positive correlation between the physicians’ prescribing cost and the information provided by the drug representative during the interaction26 Increased prescription of sponsor’s drug24 High

However, there was a significant association between attending industry-paid lunches and increased prescription of branded drugs.52 53 72

Conference travel

Pharmaceutical company-sponsored conference travels to touristic locations have quantifiable impact on the prescribing rational of attendees. A significant increase (three times) in the prescribing rate of two company drugs was observed after the physicians attended a company-sponsored symposium with all their expenses covered. Despite this significant difference in the prescribing patterns, physicians insisted there was no impact on their prescribing behaviour.57

Industry-paid lunches

Most physicians received invitations for dinners9 and free lunches.10 21 35 43 Clerks, interns and junior residents attended more company-sponsored lunches than senior residents.10 Pharmaceutical companies also sponsored departmental lunches during journal clubs.39 There was no significant association between attending industry-paid lunches37 and dinners9 and formulary request for that company’s drug (table 2).

CME sponsorship

Physicians who attended company-sponsored CME events had more positive attitudes towards and inclination to prescribe the branded drugs.28 34 43 67 69–71 We found that physicians who refused CME sponsorship were seen to prescribe higher proportion of generics and lower expenditure medicines when compared with physicians who attended CMEs.22

Discussion

We report that there is widespread interaction between the pharmaceutical industry and physicians.9–11 13 42 50 Interactions are in the form of personal communications, free gifts such as drug samples, sponsored meals, sponsored conference travel, funding for research and CMEs and honoraria.9 21 22 31 36 42 The frequency of these interactions is comparable between residents and physicians.10 21 22 36 42 However, the amount and type of gifts vary with the position of the physician in medical hierarchy, specialisation and location of practice.10 13 31 38 42 43 50 58 62 In general, trainees (residents and interns) are treated with more drug samples, stationery items and free meals than senior physicians.10 13 Senior physicians usually avail of sponsored conferences/trips, research funding, honoraria and CME events. The extent of these interactions varies with academic versus non-academic institutions: non-academic hospitals record more interactions than others.31 38 42 50 55 The majority of the physicians do not believe that they are affected by PSR interactions.1 10 32 33 35 37 43 59 However, a sizeable percentage in various surveys responded in the affirmative when asked whether they thought that their peers are vulnerable.1 20 21 37 43

Policies and educational intervention

The relationship of physicians with patients is of a fiduciary nature. Hence, activities that might affect that relationship by altering physicians’ clinical behaviour are not acceptable. Physician–pharmaceutical industry and PSR interactions may put the trust of patients in physicians at risk. Interaction with pharmaceutical industry and PSRs begins early in the physicians’ career. Trainees are exposed to pharmaceutical industry marketing and promotional techniques from the initial years of their medical education, which impact their prescribing behaviour in future. Overall, trainees, that is, residents and interns, are more vulnerable to pharmaceutical industry and PSR interactions than senior physicians11 41 62 Physicians are susceptible to pharmaceutical industry and PSR interactions, which influences their clinical decision making leading to greater prescriptions of branded drugs over low-cost generic medicines and increasing healthcare costs.22 47 52 53 72 Therefore, there is need to institute and implement stringent policies curtailing physician–pharmaceutical industry and PSR relationships, as well as educational programmes to increase awareness. Previous reports have indicated that implementing policies and conducting educational programmes are effective in increasing awareness of physician’s attitudes towards pharmaceutical industry and PSR interactions.54 59 60 73–83

Strengths and limitations of the study

A major strength of this study is that it is a large, up-to-date systematic review of studies exploring the effects of physician and pharmaceutical industry representative interactions and residents in different settings (eg, academic and primary care). Another strength of this study is the use of Cochrane and GRADE methodologies for conducting a review and assessing the quality of the studies. Moreover, we performed an extensive search in three databases and the grey literature. Some of the limitations of this review are related to the included studies, as some did not provide evidence for the significance of their findings or had varying study designs and outcomes, which made it impossible to conduct a meta-analysis. Also, the included studies were subject to risk of bias related to the lack of validity of outcome measurement and inadequate handling of significant potential confounders.

Future implications

Pharmaceutical industry and PSR interactions compromise the objectivity of the physicians. Educating physicians and increasing regulation of pharmaceutical industry and PSR interactions may lower the likelihood of prescribing new non-superior industry drugs and irrational prescription behaviour. Further studies are required to evaluate the impact of pharmaceutical industry and PSR interactions on physicians over time and the benefits of various intervention-based education programmes on the clinical and ethical behaviour of the physicians.

Supplementary Material

Reviewer comments
Author's manuscript

Footnotes

Contributors: All authors have contributed equally and have substantial contributions to the conception or design of the work: FF for the acquisition, analysis and interpretation of data for the work and drafting the work, EU and WF for revising it critically for important intellectual content and all authors contributed to final approval of the version to be published and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Competing interests: None declared.

Provenance and peer review: Not commissioned; externally peer reviewed.

Data sharing statement: Any data relevant to a published article will be made available alongside the article when published.

References

  • 1. Steinman MA, Shlipak MG, McPhee SJ. Of principles and pens: attitudes and practices of medicine housestaff toward pharmaceutical industry promotions. Am J Med 2001;110:551–7. 10.1016/S0002-9343(01)00660-X [DOI] [PubMed] [Google Scholar]
  • 2. Wazana A. Physicians and the Pharmaceutical Industry. JAMA 2000;283:373 10.1001/jama.283.3.373 [DOI] [PubMed] [Google Scholar]
  • 3. Wolfe SM. Why do american drug companies spend more than $12 billion a year pushing drugs? Is it education or promotion? J Gen Intern Med 1996;11:637–9. 10.1007/BF02599033 [DOI] [PubMed] [Google Scholar]
  • 4. Wall LL, Brown D. The high cost of free lunch. Obstet Gynecol 2007;110:169–73. 10.1097/01.AOG.0000268800.46677.14 [DOI] [PubMed] [Google Scholar]
  • 5. Chressanthis GA, Sfekas A, Khedkar P, et al. . Determinants of pharmaceutical sales representative access limits to physicians. J Med Market 2014;14:220–43. 10.1177/1745790415583866 [DOI] [Google Scholar]
  • 6. International, K. Rising costs of litigation in pharmaceutical industry. Issues Monitor-Pharmaceuticals 2011;9:1–3. [Google Scholar]
  • 7. MedAdNews. Table insert on the top 50 pharma companies. Data provided by Cegedim Strategic Data 2010.
  • 8. Mack J. Pharma promotional spending in 2013. Pharma marketing news. 2014;13. [Google Scholar]
  • 9. De Ferrari A, Gentille C, Davalos L, et al. . Attitudes and relationship between physicians and the pharmaceutical industry in a public general hospital in Lima, Peru. PLoS One 2014;9:e100114 10.1371/journal.pone.0100114 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Hodges B. Interactions with the pharmaceutical industry: experiences and attitudes of psychiatry residents, interns and clerks. CMAJ: Canadian Medial Association Journal, 1995;153:553. [PMC free article] [PubMed] [Google Scholar]
  • 11. Riese F, Guloksuz S, Roventa C, et al. . Pharmaceutical industry interactions of psychiatric trainees from 20 European countries. Eur Psychiatry 2015;30:284–90. 10.1016/j.eurpsy.2014.09.417 [DOI] [PubMed] [Google Scholar]
  • 12. Lee D, Begley CE. Physician report of industry gifts and quality of care. Health Care Manage Rev 2016;41:275–83. 10.1097/HMR.0000000000000042 [DOI] [PubMed] [Google Scholar]
  • 13. Montastruc F, Moulis G, Palmaro A, et al. . Interactions between medical residents and drug companies: a national survey after the Mediator® affair. PLoS One 2014;9:e104828 10.1371/journal.pone.0104828 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Fugh-Berman A, Ahari S. Following the script: how drug reps make friends and influence doctors. PLoS Med 2007;4:e150 10.1371/journal.pmed.0040150 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. Kesselheim AS, Mello MM, Studdert DM. Strategies and practices in off-label marketing of pharmaceuticals: a retrospective analysis of whistleblower complaints. PLoS Med 2011;8:e1000431 10.1371/journal.pmed.1000431 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Mulinari S. Unhealthy marketing of pharmaceutical products: An international public health concern. J Public Health Policy 2016;37:149–59. 10.1057/jphp.2016.6 [DOI] [PubMed] [Google Scholar]
  • 17. Othman N, Vitry AI, Roughead EE, et al. . Medicines information provided by pharmaceutical representatives: a comparative study in Australia and Malaysia. BMC Public Health 2010;10:743 10.1186/1471-2458-10-743 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. Ziegler MG. The Accuracy of Drug Information From Pharmaceutical Sales Representatives. JAMA: The Journal of the American Medical Association, 1995;273:1296. [PubMed] [Google Scholar]
  • 19. Alosaimi FD AKA, Qadi M, Albahlal A, et al. . Physicians’ attitudes towards interaction with the pharmaceutical industry/Attitudes des médecins par rapport á l’interaction avec l’industrie pharmaceutique. East Mediterr Health J 2014;20:812. [PubMed] [Google Scholar]
  • 20. Andaleeb SS, Tallman RF. Physician attitudes toward pharmaceutical sales representatives. Health Care Manage Rev 1995;20:68–76. 10.1097/00004010-199522000-00012 [DOI] [PubMed] [Google Scholar]
  • 21. Lieb K, Brandtönies S. A survey of german physicians in private practice about contacts with pharmaceutical sales representatives. Dtsch Arztebl Int 2010;107:392–8. 10.3238/arztebl.2010.0392 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. Lieb K, Scheurich A. Contact between doctors and the pharmaceutical industry, their perceptions, and the effects on prescribing habits. PLoS One 2014;9:e110130 10.1371/journal.pone.0110130 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. Francer J, Izquierdo JZ, Music T, et al. . Ethical pharmaceutical promotion and communications worldwide: codes and regulations. Philos Ethics Humanit Mede, 2014;9:7 10.1186/1747-5341-9-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. Canada., C.o.f.p.o.C.R.c.o.p.a.s.o. Guide tot enhancing referrals and consultations between physicians. College of Family Physicians of Canada 2009.
  • 25. Grande D. Limiting the influence of pharmaceutical industry gifts on physicians: self-regulation or government intervention? J Gen Intern Med 2010;25:79–83. 10.1007/s11606-009-1016-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. Brennan TA, Rothman DJ, Blank L, et al. . Health Industry Practices That Create Conflicts of Interest. JAMA 2006;295:429 10.1001/jama.295.4.429 [DOI] [PubMed] [Google Scholar]
  • 27. Spurling GK, Mansfield PR, Montgomery BD, et al. . Information from pharmaceutical companies and the quality, quantity, and cost of physicians’ prescribing: a systematic review. PLoS Med 2010;7:e1000352 10.1371/journal.pmed.1000352 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28. Lexchin J. Interactions between physicians and the pharmaceutical industry: what does the literature say? CMAJ: Canadian Medial Association Journal, 1993:14;1407–7. [PMC free article] [PubMed] [Google Scholar]
  • 29. Wazana A, Granich A, Primeau F, et al. . Using the literature in developing McGill’s guidelines for interactions between residents and the pharmaceutical industry. Acad Med 2004;79:1033–40. 10.1097/00001888-200411000-00004 [DOI] [PubMed] [Google Scholar]
  • 30. Guyatt G, Oxman AD, Akl EA, et al. . GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011;64:383–94. 10.1016/j.jclinepi.2010.04.026 [DOI] [PubMed] [Google Scholar]
  • 31. Thomson AN, Craig BJ, Barham PM. Attitudes of general practitioners in New Zealand to pharmaceutical representatives. Br J Gen Pract 1994;44:220–3. [PMC free article] [PubMed] [Google Scholar]
  • 32. Kamal S, Holmberg C, Russell J, et al. . Perceptions and Attitudes of Egyptian Health Professionals and Policy-Makers towards Pharmaceutical Sales Representatives and Other Promotional Activities. PLoS One 2015;10:e0140457 10.1371/journal.pone.0140457 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33. Gibbons RV, Landry FJ, Blouch DL, et al. . A comparison of physicians’ and patients’ attitudes toward pharmaceutical industry gifts. J Gen Intern Med 1998;13:151–4. 10.1046/j.1525-1497.1998.00048.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34. Scheffer MC. Interaction between pharmaceutical companies and physicians who prescribe antiretroviral drugs for treating AIDS. Sao Paulo Med J 2014;132:55–60. 10.1590/1516-3180.2014.1321609 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35. Brett AS, Burr W, Moloo J. Are Gifts From Pharmaceutical Companies Ethically Problematic? Arch Intern Med 2003;163:2213 10.1001/archinte.163.18.2213 [DOI] [PubMed] [Google Scholar]
  • 36. Gupta SK, Nayak RP, Sivaranjani R. A study on the interactions of doctors with medical representatives of pharmaceutical companies in a Tertiary Care Teaching Hospital of South India. J Pharm Bioallied Sci 2016;8:47 10.4103/0975-7406.171695 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37. Morgan MA, Dana J, Loewenstein G, et al. . Interactions of doctors with the pharmaceutical industry. J Med Ethics 2006;32:559–63. 10.1136/jme.2005.014480 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38. Caudill TS, Johnson MS, Rich EC, et al. . Physicians, pharmaceutical sales representatives, and the cost of prescribing. Arch Fam Med 1996;5:201–6. 10.1001/archfami.5.4.201 [DOI] [PubMed] [Google Scholar]
  • 39. Reeder M, Dougherty J, White LJ. Pharmaceutical representatives and emergency medicine residents: a national survey. Ann Emerg Med 1993;22:1593–6. 10.1016/S0196-0644(05)81266-1 [DOI] [PubMed] [Google Scholar]
  • 40. Lichstein PR, Turner RC, O’Brien K. Impact of pharmaceutical company representatives on internal medicine residency programs. A survey of residency program directors. Arch Intern Med 1992;152:1009–13. [PubMed] [Google Scholar]
  • 41. Brotzman GL, Mark DH. Policies regulating the activities of pharmaceutical representatives in residency programs. J Fam Pract 1992;34:54–8. [PubMed] [Google Scholar]
  • 42. Alssageer MA, Kowalski SR. A survey of pharmaceutical company representative interactions with doctors in Libya. Libyan J Med 2012;7:18556 10.3402/ljm.v7i0.18556 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43. Lieb K, Koch C. Medical students’ attitudes to and contact with the pharmaceutical industry: a survey at eight German university hospitals. Dtsch Arztebl Int 2013;110:584–90. 10.3238/arztebl.2013.0584 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44. Brown SR, Evans DV, Fugh-Berman A. Pharmaceutical industry interactions in family medicine residencies decreased between 2008 and 2013: a CERA study. Fam Med 2015;47:279–82. [PubMed] [Google Scholar]
  • 45. Rahman MH, Agarwal S, Tuddenham S, et al. . What do they do? Interactions between village doctors and medical representatives in Chakaria, Bangladesh. Int Health 2015;7:266–71. 10.1093/inthealth/ihu077 [DOI] [PubMed] [Google Scholar]
  • 46. Klemenc-Ketis Z, Kersnik J. Which pharmaceutical sales representatives’ features do slovenian family physicians value? Acta Inform Med 2013;21:257 10.5455/aim.2013.21.257-260 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47. Hurley MP, Stafford RS, Lane AT. Characterizing the relationship between free drug samples and prescription patterns for acne vulgaris and rosacea. JAMA Dermatol 2014;150:487 10.1001/jamadermatol.2013.9715 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48. Makowska M. Interactions between doctors and pharmaceutical sales representatives in a former communist country. The ethical issues. Camb Q Healthc Ethics 2014;23:349–55. 10.1017/S0963180113000960 [DOI] [PubMed] [Google Scholar]
  • 49. Siddiqui UT, Shakoor A, Kiani S, et al. . Attitudes of medical students towards incentives offered by pharmaceutical companies – perspective from a developing nation – a cross-sectional study. BMC Med Ethics 2014;15:36 10.1186/1472-6939-15-36 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50. Workneh BD, Gebrehiwot MG, Bayo TA, et al. . Influence of Medical Representatives on Prescribing Practices in Mekelle, Northern Ethiopia. PLoS One 2016;11:e0156795 10.1371/journal.pone.0156795 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51. Khan N, Abbas Naqvi A, Ahmad R, et al. . Perceptions and Attitudes of Medical Sales Representatives (MSRs) and Prescribers Regarding Pharmaceutical Sales Promotion and Prescribing Practices in Pakistan. J Young Pharm 2016;8:244–50. 10.5530/jyp.2016.3.13 [DOI] [Google Scholar]
  • 52. DeJong C, Aguilar T, Tseng CW, et al. . Pharmaceutical Industry-Sponsored Meals and Physician Prescribing Patterns for Medicare Beneficiaries. JAMA Intern Med 2016;176:1114 10.1001/jamainternmed.2016.2765 [DOI] [PubMed] [Google Scholar]
  • 53. Yeh JS, Franklin JM, Avorn J, et al. . Association of Industry Payments to Physicians With the Prescribing of Brand-name Statins in Massachusetts. JAMA Intern Med 2016;176:763 10.1001/jamainternmed.2016.1709 [DOI] [PubMed] [Google Scholar]
  • 54. Yeh JS, Austad KE, Franklin JM, et al. . Association of medical students’ reports of interactions with the pharmaceutical and medical device industries and medical school policies and characteristics: a cross-sectional study. PLoS Med 2014;11:e1001743 10.1371/journal.pmed.1001743 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55. Parikh K, Fleischman W, Agrawal S. Industry relationships with pediatricians: Findings from the open payments sunshine act. Pediatrics 2016;137:e20154440 10.1542/peds.2015-4440 [DOI] [PubMed] [Google Scholar]
  • 56. Spingarn RW, Berlin JA, Strom BL. When pharmaceutical manufacturersʼ employees present grand rounds. what do residents remember? Acad Med 1996;71:86–8. [DOI] [PubMed] [Google Scholar]
  • 57. Orlowski JP, Wateska L. The effects of pharmaceutical firm enticements on physician prescribing patterns. There’s no such thing as a free lunch. Chest 1992;102:270–3. [DOI] [PubMed] [Google Scholar]
  • 58. Zaki NM. Pharmacists’ and physicians’ perception and exposure to drug promotion: A Saudi study. Saudi Pharm J 2014;22:528–36. 10.1016/j.jsps.2014.02.008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59. Randall ML, Rosenbaum JR, Rohrbaugh RM, et al. . Attitudes and behaviors of psychiatry residents toward pharmaceutical representatives before and after an educational intervention. Acad Psychiatry 2005;29:33–9. 10.1176/appi.ap.29.1.33 [DOI] [PubMed] [Google Scholar]
  • 60. Esmaily HM, Silver I, Shiva S, et al. . Can rational prescribing be improved by an outcome-based educational approach? A randomized trial completed in Iran. J Contin Educ Health Prof 2010;30:11–18. 10.1002/chp.20051 [DOI] [PubMed] [Google Scholar]
  • 61. Chren MM, Landefeld CS. Physicians’ behavior and their interactions with drug companies. A controlled study of physicians who requested additions to a hospital drug formulary. JAMA 1994;271:684. [PubMed] [Google Scholar]
  • 62. Zipkin DA, Steinman MA. Interactions between pharmaceutical representatives and doctors in training. A thematic review. J Gen Intern Med 2005;20:777–86. 10.1111/j.1525-1497.2005.0134.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63. McMurray RJ. Gifts to Physicians From Industry. JAMA: The Journal of the American Medical Association, 1991;265:501. [Google Scholar]
  • 64. Lotfi T, Morsi RZ, Rajabbik MH, et al. . Knowledge, beliefs and attitudes of physicians in low and middle-income countries regarding interacting with pharmaceutical companies: a systematic review. BMC Health Serv Res 2016;16:57 10.1186/s12913-016-1299-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65. Fischer MA, Keough ME, Baril JL, et al. . Prescribers and pharmaceutical representatives: why are we still meeting? J Gen Intern Med 2009;24:795–801. 10.1007/s11606-009-0989-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66. Chimonas S, Brennan TA, Rothman DJ. Physicians and drug representatives: exploring the dynamics of the relationship. J Gen Intern Med 2007;22:184–90. 10.1007/s11606-006-0041-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67. Saito S, Mukohara K, Bito S. Japanese practicing physicians’ relationships with pharmaceutical representatives: a national survey. PLoS One 2010;5:e12193 10.1371/journal.pone.0012193 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68. Lurie N, Rich EC, Simpson DE, et al. . Pharmaceutical representatives in academic medical centers. J Gen Intern Med 1990;5:240–3. 10.1007/BF02600542 [DOI] [PubMed] [Google Scholar]
  • 69. Bowman MA, Pearle DL. Changes in drug prescribing patterns related to commercial company funding of continuing medical education. J Contin Educ Health Prof 1988;8:13–20. 10.1002/chp.4750080104 [DOI] [PubMed] [Google Scholar]
  • 70. Grundy Q, Bero L, Malone R. Interactions between non-physician clinicians and industry: a systematic review. PLoS Med 2013. 2013;10:e1001561 10.1371/journal.pmed.1001561 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71. Dixon D, Takhar J, Macnab J, et al. . Controlling quality in CME/CPD by measuring and illuminating bias. J Contin Educ Health Prof 2011;31:109–16. 10.1002/chp.20114 [DOI] [PubMed] [Google Scholar]
  • 72. Steinbrook R. Industry Payments to Physicians and Prescribing of Brand-name Drugs. JAMA Intern Med 2016;176:1123 10.1001/jamainternmed.2016.2959 [DOI] [PubMed] [Google Scholar]
  • 73. Larkin I, Ang D, Avorn J, et al. . Restrictions on pharmaceutical detailing reduced off-label prescribing of antidepressants and antipsychotics in children. Health Aff 2014;33:1014–23. 10.1377/hlthaff.2013.0939 [DOI] [PubMed] [Google Scholar]
  • 74. Chressanthis GA, Khedkar P, Jain N, et al. . Can access limits on sales representatives to physicians affect clinical prescription decisions? A study of recent events with diabetes and lipid drugs. J Clin Hypertens 2012;14:435–46. 10.1111/j.1751-7176.2012.00651.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75. Silverman E. Everything you need to know about the Sunshine Act. BMJ 2013;347:f4704 10.1136/bmj.f4704 [DOI] [PubMed] [Google Scholar]
  • 76. Shalowitz DI, Spillman MA, Morgan MA. Interactions with industry under the Sunshine Act: an example from gynecologic oncology. Am J Obstet Gynecol 2016;214:703–7. 10.1016/j.ajog.2016.02.035 [DOI] [PubMed] [Google Scholar]
  • 77. Norris P HA, Lexchin J, et al. . Drug promotion—what we know, what we have yet to learn—reviews of materials in the WHO/HAI database on drug promotion. EDM Research Series 2005. [Google Scholar]
  • 78. Carroll AE, Vreeman RC, Buddenbaum J, et al. . To what extent do educational interventions impact medical trainees’ attitudes and behaviors regarding industry-trainee and industry-physician relationships? Pediatrics 2007;120:e1528–35. 10.1542/peds.2007-0363 [DOI] [PubMed] [Google Scholar]
  • 79. Birkhahn RH, Jauch E, Kramer DA, et al. . A review of the federal guidelines that inform and influence relationships between physicians and industry. Acad Emerg Med 2009;16:776–81. 10.1111/j.1553-2712.2009.00460.x [DOI] [PubMed] [Google Scholar]
  • 80. Sergeant MD HP, Godwin M, Walker DM, et al. ; Interactions with the pharmaceutical industry: a survey of family medicine residents in Ontario. CMAJ: Canadian Medial Association Journal, 1996;155:1243. [PMC free article] [PubMed] [Google Scholar]
  • 81. T Montague B, Fortin VI AH, Rosenbaum J. A systematic review of curricula on relationships between residents and the pharmaceutical industry. Med Educ 2008;42:301–8. 10.1111/j.1365-2923.2007.02998.x [DOI] [PubMed] [Google Scholar]
  • 82. R. P., Guidelines for faculity involvement in commercially supported continuing medical-education. Acad Med 1992. [PubMed] [Google Scholar]
  • 83. Greenland P. Time for the Medical Profession to Act. Arch Intern Med 2009;169:829 10.1001/archinternmed.2009.72 [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Appendix 1

bmjopen-2017-016408supp001.pdf (317.1KB, pdf)

Supplementary material 2

bmjopen-2017-016408supp002.pdf (179.5KB, pdf)

Reviewer comments
Author's manuscript

Articles from BMJ Open are provided here courtesy of BMJ Publishing Group

RESOURCES